`
`Filed: April 17, 2015
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`METRICS, INC., MAYNE PHARMA, and JOHNSON MATTHEY, INC.,
`Petitioner
`v.
`
` SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
`BAUSCH & LOMB PHARMA HOLDINGS CORP.,
`Patent Owner
`_________________
`Case IPR2014-01043
`U.S. Patent 8,669,290
`_________________
`
`PATENT OWNER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2014-01043
`U.S. Patent 8,669,290
`Further to 37 C.F.R. § 42.63(e), Patent Owner Senju Pharmaceutical Co.,
`
`Ltd., hereby submits a current listing of Senju Exhibits to counsel for Petitioner
`
`Metrics, Inc..
`
`Exhibits
`Exhibit 2001
`
`Exhibit 2002
`Exhibit 2003
`
`Exhibit 2004
`
`Description
`Paragraph IV Certification Notice Letter from Coastal
`Pharmaceuticals, Inc. (“Coastal”) to Senju (June 26, 2014)
`(challenging the ’431 patent and the ’290 patent).
`Letter from Metrics to Senju (Mar. 13, 2014).
`Coastal’s Reply Brief to Plaintiff’s Opposition to Defendant’s
`Motion to Dismiss the Complaint, Senju Pharm. Co. v. Metrics,
`Inc., No. 1:14-CV-03962-JBS-KMW (D.N.J. filed June 20, 2014)
`(No. 51).
`Transcript of Oral Hearing, Senju Pharm. Co. v. Metrics, Inc., No.
`1:14-CV-03962-JBS-KMW (D.N.J. filed June 20, 2014) (No. 63).
`Prosecution History of the ’431 Patent (excerpted).
`Exhibit 2005
`Prosecution History of the ’290 patent (excerpted).
`Exhibit 2006
`Exhibit 2007 U.S. Patent No. 5,475,034 (filed Jun. 6, 1994) (Yanni et al.).
`Exhibit 2008 WO Patent No. 0115677 A2 (filed Aug. 31, 1999) ( Gamache et
`al.).
`Clinics & Drug Therapy, Vol. 20, No. 10, Oct. 2000.
`Letter from Renata Albrecht, MD, Director, Division of Transplant
`and Ophthalmology Products, Center for Drug Evaluation and
`Research, U.S. Food and Drug Administration, to Bausch & Lomb,
`Inc. (Apr. 5, 2014) (The FDA’s Approval of Prolensa®).
`Press Release, Drugs.com, FDA Approves Prolensa® (posted April
`2013).
`Bausch & Lomb Package Label for Prolensa® (revised Apr. 2,
`2013)
`[Reserved].
`[Reserved].
`[Reserved].
`Brief of Plaintiff in Support of Motion for Order Enjoining
`Defendants From Prosecuting Parallel Inter Partes Review
`
`Exhibit 2009
`Exhibit 2010
`
`Exhibit 2011
`
`Exhibit 2012
`
`Exhibit 2013
`Exhibit 2014
`Exhibit 2015
`Exhibit 2016
`
`
`
`2
`
`
`
`Exhibit 2017
`
`Exhibit 2018
`
`Exhibit 2019
`
`Exhibit 2020
`
`Case IPR2014-01043
`U.S. Patent 8,669,290
`Proceedings, Senju Pharm. Co. v. Metrics, Inc., No. 1:14-CV-
`03962-JBS-KMW (D.N.J. filed June 20, 2014) (No. 10-1).
`Complaint, Senju Pharm. Co. v. Metrics, Inc., No. 1:14-CV-03962-
`JBS-KMW (D.N.J. filed June 20, 2014) (No. 1).
`Letter from Elizabeth J. Holland, Counsel for Lupin Ltd., to Senju
`(May 13, 2014) (Lupin’s Paragraph IV Certification Notice Letter
`challenging the ’290 patent).
`Letter from Elizabeth J. Holland, Counsel for Lupin Ltd., to Senju
`(Dec. 19, 2013) (Lupin’s Paragraph IV Certification Notice Letter
`challenging the ’431 patent).
`Reply Brief of Plaintiff in support of its Motion for Order
`Enjoining Defendants from Prosecuting Parallel Inter Partes
`Review Proceedings, Senju Pharm. Co. v. Metrics, Inc., No. 1:14-
`CV-03962-JBS-KMW (D.N.J. filed June 20, 2014) (No. 49).
`Resume of Stephanie Box, available at
`http://cdn.proz.com/profile_resources/060862_r47b495b8172cc.pdf
`(last visited Nov. 18, 2014).
`Exhibit 2022 U.S. Food and Drug Administration, Orange Book: Approved Drug
`Products with Therapeutic Equivalence Evaluations, Patent and
`Exclusivity Search Results from query on Appl No 203168 Product
`001 in the OB_Rx list, available at http://www.accessdata.fda.gov/
`scripts/cder/ob/docs/patexclnew.cfm?Appl_No=203168&Product_
`No=001&table1=OB_Rx (last visited Nov. 20, 2014) (Prolensa®
`Orange Book-listed patents).
`Exhibit 2023 Orange Book listing of Coastal Pharmaceuticals’ Filing of Generic
`Drug Products,
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempah.cfm
`(last visited January 26, 2015).
`Coastal Pharmaceuticals’ Articles of Incorporation
`Teleconference Transcript of Initial Conference Call, dated March
`17, 2015
`Transcript of Teleconference with the Board, dated April 15, 2015
`
`Exhibit 2021
`
`Exhibit 2024
`Exhibit 2025
`
`Exhibit 2026
`
`3
`
`
`
`
`
`
`
`Dated: April 17, 2015
`
`
`
`Case IPR2014-01043
`U.S. Patent 8,669,290
`Respectfully submitted,
`
`By: /Jonathan R.K. Stroud/
`Bryan C. Diner, Lead Counsel
`Reg. No. 32,409
`M. Andrew Holtman, Back-up Counsel
`Reg. No. 53,032
`Justin J. Hasford, Back-up Counsel
`Reg. No. 62,180
`Jonathan R.K. Stroud, Back-up Counsel
`Reg. No. 72,518
`Finnegan, Henderson, Farabow, Garrett
` & Dunner, L.L.P.
`901 New York Ave. NW
`Washington, DC 20001-4413
`(202) 408-4000
`
`Counsel for Patent Owner
`
`
`
`4
`
`
`
`CERTIFICATE OF SERVICE
`
`Case IPR2014-01041
`U.S. Patent 8,129,431
`
`The undersigned hereby certifies that a copy of the foregoing Patent
`
`Owner’s Updated Exhibit List and Exhibit 2026 were served on April 17, 2015,
`
`via email directed to counsel of record for the Petitioner at the following:
`
`Patrick D. McPherson
`PDMcPherson@duanemorris.com
`
`Vincent L. Capuano
`VCapuano@duanemorris.com
`
`
`
`Date: April 17, 2015
`
`/Lisa C. Hines/
`Lisa C. Hines
`Litigation Clerk
`
`Finnegan, Henderson, Farabow, Garrett &
`Dunner, LLP
`
`
`
`
`
`5